Testing effectiveness (Phase 2)Active Not RecruitingNCT06391944
What this trial is testing
JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations
Who this might be right for
Local Advanced or Metastatic NSCLCHarboring EGFR Common Mutation
Shanghai JMT-Bio Inc. 161